Fujifilm has cited strong demand for process development and manufacturing work at its Denmark site as a key driver in its fiscal year 2022 results. For the full year ending 31 March 2023, Fujifilm Corporation reported sales in its healthcare division of ¥918 billion ($6.7 billion), up 14.5% on the year prior. Within the segment, the firm’s bio contract development and manufacturing organization (CDMO) businesses grew 29.2% year-on-year, pulling in ¥194 billion ($1.43 billion). “Revenue rose due mainly to strong…

ImmPACT Bio has opened a facility in LA to support IMPT-314, a CD19/CD20 bispecific CAR-T candidate for B-cell mediated malignancies and autoimmune diseases. The 21,500 square-foot facility in West Hills, Los Angeles includes two manufacturing suites dedicated to autologous cell therapy drug manufacturing, a QC lab, and space for future cleanroom expansion. The $15 million investment will support lead candidate IMPT-314 by accelerating clinical supply as the firm evolves its process and integrates automation. The chimeric antigen receptor (CAR) T-cell…